Related Experiment Video

Updated: May 5, 2026

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro
07:03

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro

Published on: June 16, 2022

6.5K

8-Epixanthatin Suppresses RANKL-Induced Osteoclast Differentiation via Inhibition of NF-κB and MAPK Signaling

Lifang Zhang1,2, Vishwa Deepak1,2,3,4,5,6

  • 1Osteoimmunology and Drug Discovery Research Group, Department of Biology, College of Science, Mathematics and Technology, Wenzhou-Kean University, 88 Daxue Road, Wenzhou 325060, China.

International Journal of Molecular Sciences
|May 4, 2026
PubMed

Insights

8-Epixanthatin effectively inhibits osteoclast differentiation, a key process in bone destruction. This compound shows promise as a novel anti-resorptive agent by targeting key signaling pathways involved in bone metabolism.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cell Biology

Background:

  • Osteoclast hyperactivity drives pathological bone destruction.
  • Novel anti-resorptive compounds are crucial for treating bone diseases.

Purpose of the Study:

  • To investigate the potential of 8-Epixanthatin as an inhibitor of osteoclast differentiation.
  • To explore the underlying mechanisms of 8-Epixanthatin's anti-osteoclastogenic effects.

Main Methods:

  • Assessing the effect of 8-Epixanthatin on receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclast differentiation.
  • Evaluating compound cytotoxicity.
  • Measuring TRAP-positive multinucleated osteoclasts.
  • Investigating the impact on nuclear factor kappa-B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways.

Main Results:

  • 8-Epixanthatin demonstrated no significant cytotoxicity at effective concentrations.
  • The compound exhibited concentration-dependent inhibition of osteoclast formation with an IC50 of 2.3 μM.
  • Mechanistic studies indicated interference with RANKL-activated NF-κB and MAPK signaling cascades.

Conclusions:

  • 8-Epixanthatin is a potent inhibitor of osteoclast differentiation.
  • The compound's mechanism involves modulation of key signaling pathways.
  • 8-Epixanthatin represents a promising lead structure for developing new anti-osteoclast drugs.
Keywords:
bone resorptionmitogen-activated protein kinase (MAPK)natural compoundsnuclear factor κB (NF-κB)osteoclast differentiationosteoporosisreceptor activator of nuclear factor kappa-B ligand (RANKL)

More Related Videos

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

8.8K
Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes11:52

Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes

Published on: January 27, 2023

6.0K

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.6K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
NF-kB-dependent Signaling Pathway02:26

NF-kB-dependent Signaling Pathway

2.0K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.9K